Skip to content

Drug interactions

Idelalisib + Repaglinide

Severity: Major

Idelalisib and Repaglinide: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Idelalisib is a strong CYP3A inhibitor and can substantially increase repaglinide exposure. This raises the risk of significant hypoglycemia.

What this interaction means in plain words

Idelalisib and Repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Idelalisib belongs to Oncology; Repaglinide belongs to Endocrine.

Evidence level: Moderate

Why it happens

Idelalisib strongly inhibits CYP3A4, reducing repaglinide metabolism.

What to do

Avoid the combination where possible by using an alternative antidiabetic agent. If used together, reduce the repaglinide dose and monitor blood glucose frequently.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Idelalisib and Repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Idelalisib with Repaglinide?

MediHelp rates the interaction as major. Idelalisib and Repaglinide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Idelalisib is a strong CYP3A inhibitor and can substantially increase repaglinide exposure. This raises the risk of significant hypoglycemia.

How serious is the interaction between Idelalisib and Repaglinide?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible by using an alternative antidiabetic agent. If used together, reduce the repaglinide dose and monitor blood glucose frequently.

What other medicines interact with Repaglinide?

MediHelp also lists interactions of Repaglinide with, for example, Gemfibrozil, Clarithromycin, Clopidogrel. The full list is on the Repaglinide page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in